Infectious Dis. Medical News about Caspofungin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Caspofungin for the treatment of candidaemia in patients with haematological malignancies
Clinical Microbiology and Infection, 06/29/09

Pagano L et al. - In a study to evaluate the efficacy of caspofungin in neutropenic pts with haematological malignancies (HM) and candidaemia, results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.

Methods

This study was prospectively conducted in 11 haematology divisions over a 2-yr period to evaluate the efficacy of caspofungin in 24 neutropenic pts with haematological malignancies (HM) and candidaemia.

Results

Pts had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 109/L) for a median of 12 days (2–41) before candidaemia.
Pts received caspofungin for a median duration of 12 days, obtaining a favourable overall response of 58%.
At 30 days, 11 pts had died (46%); candidaemia was responsible for mortality in 6 pts (25%).

<< Previous
Ways patients are cutting health care costs

Next >>
Safety and Outcomes of Open-Label Deferasirox Iron Chelation...